Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619797 | 1.00 | TYR (0.47) | TYRCHRM2CHRM3PDK1MEN1 | |
| SCHEMBL7245757 | 0.79 | TYR (0.54) | TYRCHRM2CHRM3PDK1OPRD1 | |
| SCHEMBL7245773 | 0.79 | TYR (0.54) | TYRCHRM2CHRM3PDK1OPRD1 | |
| SCHEMBL28891615 | 0.79 | MEN1 (0.54) | CHRM2CHRM3MEN1KMT2AKDM4E | |
| SCHEMBL6799615 | 0.77 | TYR (0.46) | TYRCHRM2CHRM3PDK1MEN1 | |
| SCHEMBL6802537 | 0.77 | TYR (0.46) | TYRCHRM2CHRM3PDK1MEN1 | |
| SCHEMBL6799618 | 0.77 | TYR (0.46) | TYRCHRM2CHRM3PDK1MEN1 | |
| SCHEMBL28017518 | 0.76 | CHRM2 (0.50) | TYRCHRM2CHRM3MEN1KMT2A | |
| SCHEMBL19249421 | 0.75 | TYR (0.48) | TYRMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL6806765 | 0.74 | OPRM1 (0.56) | TYROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3950046-B2 | — | — | 2007-07-25 | — | — | JP | claimed |
| JP-2004509154-A | — | — | 2004-03-25 | — | — | JP | claimed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | claimed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2007095630-A2 | NEW UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885CHRM2 3548/4885CHRM3 3836/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885CHRM2 3548/4885CHRM3 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.